leisure time -WSS

leisure time

author：comprehensive 2025-09-30 00:48:15 - browse：2639

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Medical student insurance fails on mental health care coverage

entertainment

WSS

Intarcia’s device

Thermo Fisher plant for manufacturing gene therapies to expand

Tome Biosciences co

Second xenotransplant done with gene

It's been 20 years since Dolly the sheep. Where's my clone?

ACIP vaccine advisory panel sees its vacancies filled

focus

leisure time

focus

Apple is now the first public company to be valued at $3 trillion

Tome Biosciences co

State Dept. review finds Biden bears some blame for Afghanistan failures

Second xenotransplant done with gene

Malaria cases in Florida and Texas: Here’s what you need to know

Eli Lilly reports tirzepatide MASH success during Q4 earnings

BioMarin wins approval for gene therapy to treat hemophilia A

Lasker Awards 2023: Winners in biomedical research

How one medical school became remarkably diverse

Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

STAT Virtual Event: Putting AI to the Test

Ebola vaccine can save some who are already sick, per new study

Medical student insurance fails on mental health care coverage

Eli Lilly reports tirzepatide MASH success during Q4 earnings

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Congress must protect the remaining independent doctors

leisure time

focus

entertainment

hotspot